Podcast Series on Herpes Zoster Prevention: Pearls for Clinicians Managing Patients With Immune-mediated Diseases

Shingles, also called herpes zoster (HZ), is a painful rash that develops due to reactivation of the varicella zoster virus, which causes chicken pox. Approximately 1 in 3 individuals in the United States will develop shingles during their lifetime, with adults over 50 years of age and immunocompromised individuals being at highest risk. Recent developments in HZ prevention include a new recombinant zoster vaccine, which is now recommended as the preferred shingles vaccine in updated guidelines from the Advisory Committee on Immunization Practices (ACIP). Effective prevention and risk management strategies are particularly important for patients with immune-mediated diseases. In this CME podcast series, experts will review the clinical aspects and primary risk factors for HZ, discuss optimized use of vaccines for at-risk populations, and provide guidance on effective patient education strategies to enhance vaccine uptake.

Cost: Free

View Offer chevron_right

Key Features

  • Free
  • 1.0 AMA PRA Category 1 Credit(s)™
  • 1 AAPA Category 1 CME credits
  • The My Healio CME Dashboard keeps track of earned credits and saved activities
  • Personalized recommendations make finding your next activity easy
  • Over 50,000 of your colleagues know that earn credits is faster and easier with Healio CME

Topics Covered

  • Shingles
  • Herpes zoster (HZ)
  • Varicella zoster virus
  • Chicken pox
  • Immunocompromised
  • Recombinant zoster vaccine
  • Advisory Committee on Immunization Practices (ACIP)
  • Immune-mediated diseases
  • Rheumatology
  • Gastroenterology
  • Dermatology

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

-Identify the clinical aspects and primary risk factors for herpes zoster (HZ) to enhance the use of vaccines in patients who are at high risk for infection.
-Implement effective prevention strategies and patient education to increase herpes zoster vaccine uptake and compliance.

Target Audience

The intended audience for this activity is rheumatologists, gastroenterologists, dermatologists, physician assistants, nurse practitioners, and other health care professionals involved in the management of patients with herpes zoster.

Additional credit info

This continuing medical education activity is provided by Vindico Medical Education

Support Statement
This educational activity is supported by an educational grant from GlaxoSmithKline.

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is approved for 1.0 contact hour(s) of continuing education (which includes 1.0 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20104561. This activity was planned in accordance with AANP Accreditation Standards and Policies.

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid from 10/31/2020 to 10/30/2021. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-201379.

This enduring material is approved for 1 year from the date of original release, October 31, 2020 to October 30, 2021.

Stay up-to-date

Receive special offers, keep up with MOC requirements and stay informed of the latest offerings in free online CME in your specialty.